N. B. Leighl

991 citations
32 papers · 758 indexed · 1 hit paper · h-index 11
Topics
Lung Cancer Treatments and Mutations (23 papers)Cancer Genomics and Diagnostics (10 papers)Lung Cancer Diagnosis and Treatment (8 papers)

In The Last Decade

N. B. Leighl

29 papers receiving 736 citations

Hit Papers

Overall survival with cisplatin–gemcitabine and bevacizum...20102026201520202010100200300400

Peers

N. B. Leighl
Comparison fields: 5 of 61
  • Pulmonary and Respiratory Medicine 568
  • Oncology 498
  • Molecular Biology 206
  • Cancer Research 128
  • Pathology and Forensic Medicine 67
Replace Osvaldo Rudy Aren with:
Osvaldo Rudy Aren Chile
Monica Giovannini Italy
Shuta Ohara Japan
P. Fidias United States
V. Gorbounova Russia
Lin Shen China
C. Blajman Argentina
Sook Jung Jo South Korea
Graham Temple United Kingdom
Claudia-Nanette Gann Germany
N. B. Leighl relative to Osvaldo Rudy Aren Chile Osvaldo Rudy Aren's profile →
Citations per field
00.5×1.5×
Osvaldo Rudy Aren · 1×
Citations per year

Countries citing papers authored by N. B. Leighl

Since Specialization
Citations

This map shows the geographic impact of N. B. Leighl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. B. Leighl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. B. Leighl more than expected).

Fields of papers citing papers by N. B. Leighl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. B. Leighl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. B. Leighl. The network helps show where N. B. Leighl may publish in the future.

Co-authorship network of co-authors of N. B. Leighl

This figure shows the co-authorship network connecting the top 25 collaborators of N. B. Leighl. A scholar is included among the top collaborators of N. B. Leighl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. B. Leighl. N. B. Leighl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 20
2 0
3 0
4 37
5 21
6 1
7 11
8 2
9
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)breakdown →
498
10 15
11 15
12 4
13 13
14 24
15 3
16 2
17 2
18 10
19 6
20 6

About N. B. Leighl

N. B. Leighl is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology, having authored 32 papers that have together received 758 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (23 papers), Cancer Genomics and Diagnostics (10 papers) and Lung Cancer Diagnosis and Treatment (8 papers). The work is most often cited by research in Oncology (498 citations), Pulmonary and Respiratory Medicine (568 citations) and Cancer Research (128 citations). N. B. Leighl has collaborated with scholars based in United States, Canada and Czechia. Frequent co-authors include Martin Reck, Rodryg Ramlau, J. Mezger, Petr Zatloukal, Joachim von Pawel, Vera Hirsh, Norman C. Moore, Venice Archer, C. Manegold and V. Gorbounova. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026